Literature DB >> 16285474

Detection and identification of significant ANAs in previously determined ANA negative samples.

Kara Kidd1, Karen Cusi, Ruth Mueller, Megan Goodner, Bob Boyes, Eric Hoy.   

Abstract

BACKGROUND: An antinuclear antibody (ANA) substrate transfected with the cDNA to hyperexpress the 60 kD SS-A/Ro antigen (HEp-2000) has been shown to detect anti-SS-A/Ro antibodies missed by standard HEp-2 and other immunoassays. Despite this evidence, many laboratories remain convinced that with experienced technicians, standard HEp-2 is acceptable for ANA detection. AIM: To challenge the ability of HEp-2000 to detect anti-SS-A/Ro antibodies in samples previously determined to be ANA negative using standard HEp-2.
METHODS: Three hundred and seventy-one pre-screened "negative" ANA samples were provided by a university hospital laboratory in Germany. These samples were tested on the HEp-2000 substrate at a dilution of 1:40 by indirect immunofluorescence (IIF). Samples that screened positive for a nuclear pattern were titered (range of 1:40-1:640) and all ANA-positive patterns were identified. Samples containing at least one positive ANA pattern at a dilution greater than or equal to 1:160 were further tested. Samples that produced a speckled pattern were tested for antibodies to the extractable nuclear antigens (ENA) and samples that showed homogeneous staining were tested for antibodies to dsDNA, and if negative, were then tested for anti-histone antibodies.
RESULTS: Ninety-one patient samples were positive with titers > or =1:160. Speckled patterns were the most common finding (30 samples) followed by speckled/homogeneous mixed patterns (19 samples) and samples demonstrating the SS-A/Ro pattern (16 samples) either alone or in combination with other ANA patterns. The remaining 26 positive samples consisted of various other ANA patterns. The most commonly identified ENAs were SS-A/Ro (14 samples), Scl-70 (11 samples) and SSB (6 samples). No antibodies to dsDNA were identified in 23 positive samples with homogeneous staining patterns, though 17 of these samples tested positive for antibodies to histone.
CONCLUSIONS: HEp-2000 detected anti-SS-A/Ro antibodies in 16 (4%) of the "ANA negative" samples. In addition to improved sensitivity for anti-SS-A antibodies, HEp-2000 demonstrated improved sensitivity over standard HEp-2 substrate for other significant ANAs including anti-Scl-70, anti-histone, and anti-SS-B antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16285474

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  5 in total

1.  AIT test has no problem in the detection of anti-ribosomal P--authors' response.

Authors:  Michael Mahler; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2009-08-25       Impact factor: 5.156

2.  Validation of the 2019 ACR/EULAR classification criteria of systemic lupus erythematosus in 100 Japanese patients: a real-world setting analysis.

Authors:  Masei Suda; Mitsumasa Kishimoto; Sachiko Ohde; Masato Okada
Journal:  Clin Rheumatol       Date:  2020-02-12       Impact factor: 2.980

Review 3.  Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.

Authors:  Michael Mahler; Pier-Luigi Meroni; Xavier Bossuyt; Marvin J Fritzler
Journal:  J Immunol Res       Date:  2014-04-27       Impact factor: 4.818

4.  Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies.

Authors:  Michael Mahler; Jennifer T Ngo; Johannes Schulte-Pelkum; Tanja Luettich; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2008-11-11       Impact factor: 5.156

5.  Relationships among Antibodies against Extractable Nuclear Antigens, Antinuclear Antibodies, and Autoimmune Diseases in a Brazilian Public Hospital.

Authors:  Fernanda Weyand Banhuk; Bruna Corrêa Pahim; Alex Sandro Jorge; Rafael Andrade Menolli
Journal:  Autoimmune Dis       Date:  2018-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.